Connect with us

Business

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

Published

on

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry


President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, Dec. 19, 2025.

Will Oliver | Bloomberg | Getty Images

Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0.

Those are among the themes that dominated conversations last week as drugmakers of all sizes met with investors to map out their plans for 2026 and beyond at the annual JPMorgan Healthcare Conference in San Francisco. 

After geopolitical uncertainty weighed on dealmaking during the first half of 2025, investors and drugmakers sounded optimistic that 2026 may mark a turning point for the sector. Investors are beginning to see signs of recovery in U.S. biotech so far this year after years of volatility, betting that lower interest rates and a renewed appetite for deals will reopen the IPO window.

The conference lacked the splashy, high-dollar acquisitions that typically take center stage there. But big pharma made it clear it is on the hunt for potential buyouts and collaborations as it looks to make up for roughly $300 billion in possible lost revenue as patents for blockbuster drugs expire toward the end of the decade. 

Some concerns around President Donald Trump‘s health-care policy agenda have eased after more than a dozen major drugmakers ended 2025 with landmark drug pricing deals and three-year reprieves from tariffs.

When asked about whether he still held to his prediction last year that Trump will be a positive for the sector, Pfizer CEO Albert Bourla told reporters last week, “Yes,” even though “I got scared big time” along the way.

Still, investors are trying to understand how the drug pricing agreements will impact businesses, and parse out the implications of policy changes like softer U.S. vaccine recommendations. 

Here’s what we heard from pharma executives about the year ahead. 

Drug pricing 

Sanofi CEO Paul Hudson speaks during an event held by President Donald Trump to make an announcement about lowering drug prices, at the Roosevelt Room of the White House in Washington, Dec. 19, 2025.

Evelyn Hockstein | Reuters

AstraZeneca expects the initial effects of its drug pricing deal to be limited and manageable, as it so far applies to a specific Medicaid population and represents “a low single-digit percentage” of the company’s global sales, said CFO Aradhana Sarin during a presentation on Jan. 13. 

Meanwhile, Bourla told reporters on Jan. 12 that the deals will help companies pressure European countries to increase what they will pay for drugs, similar to how the U.K. agreed in December to raise prices for medicines as part of a trade deal with the U.S.

He said companies could stop supplying medicines to some countries that refuse to pay more. 

“Do you reduce [U.S.] prices to France’s level or stop supplying France? You stop supplying France,” Bourla said. “So they will stay without new medicines … because the system will force us not to be able to accept the lower prices.”

Patent losses, dealmaking

Pharmaceutical companies were confident they will be able to offset losses from upcoming patent expirations of popular drugs and zeroed in on dealmaking as a critical tool to add new revenue. Cheaper generic versions of brand-name drugs typically enter the market after their patents expire, leading to significant price drops and a loss of market share over time due to increased competition.

During a presentation on Jan. 12, Merck CEO Rob Davis said his company hopes “to grow through” the upcoming loss of exclusivity for its top-selling cancer immunotherapy Keytruda. 

Merck raised its outlook for new products, saying those items will contribute a projected $70 billion in sales by the mid-2030s. That is almost double what Wall Street expects Keytruda to record in 2028 before its patent expires. Keytruda generated $29.48 billion in sales in 2024, which was nearly half of Merck’s total revenue for that year.

Davis indicated that Merck may not be done with dealmaking, especially for later-stage or already-approved products. 

“If you look from a dollar perspective, we’ve been looking in that up to $15 billion dollar range,” he said. “We’ve been very clear that we’re willing to go larger than that, but we only will do so following the exact same logic and discipline.”

Bristol Myers Squibb has the highest exposure to the upcoming loss of exclusivity cycle, with blockbuster drugs such as the blood thinner Eliquis set to face generic competition, according to a note from JPMorgan analysts in late December. Eliquis raked in $13.3 billion in sales in 2024, making up more than a quarter of the company’s revenue for the year.

But in an interview on Jan. 13, Bristol Myers Squibb CEO Chris Boerner said the company has the potential to deliver up to 10 new products by the end of the decade.

“We feel really good about the substrate we have in late-stage development, and the mid-stage pipeline is also progressing nicely,” he told CNBC. 

Boerner highlighted 11 late-stage data readouts in 2026 across six potential new products. Boerner said the company is “casting a wide net” for its business development.

He added that Bristol Myers Squibb is hoping to build on the core therapeutic areas it knows well, look across different phases of development and focus on “the best, most innovative science that we can find” to tackle difficult-to-treat diseases. 

This year, Novo Nordisk is also facing patent expirations for semaglutide — the active ingredient in its blockbuster diabetes drug Ozempic and obesity counterpart Wegovy — in certain countries, including Canada and China. 

Novo Nordisk CEO Mike Doustdar said 2026 “will be the year of price pressure” due to generic competition in some international markets and its U.S. drug pricing deal. He added that Novo Nordisk aims to offset price cuts with volume growth and will be active in business development to see what “can complement our own pipeline.” 

Those comments come after Novo Nordisk lost a heated bidding war with Pfizer last year over the obesity biotech Metsera.

Vaccine rhetoric 

Health and Human Services Secretary Robert F. Kennedy Jr. announces new nutrition policies during a press conference at the Department of Health and Human Services in Washington, Jan. 8, 2026.

Jonathan Ernst | Reuters

Some executives reiterated concerns about the administration’s changes to U.S. immunization policy under Health and Human Services Secretary Robert F. Kennedy Jr. — a prominent vaccine skeptic — and his appointees. That includes the Centers for Disease Control and Prevention’s recent move to roll back the number of immunizations routinely recommended for children. 

“I’m very annoyed. I’m very disappointed,” Pfizer’s Bourla said, adding that “what is happening has zero scientific merit and is just serving an agenda, which is political.” 

He added, “I think we do see that there are reductions in vaccination rates of kids and that will raise diseases, and I’m certain about that.” But Bourla said he doesn’t believe the recent changes to the childhood vaccine schedule will impact Pfizer’s bottom line. 

He said the pressure the administration is putting on immunizations “is an anomaly that will correct itself.” 

Meanwhile, Sanofi’s Hudson said the scrutiny of vaccines by the Trump administration is aligned with what the company expected ahead of the 2024 election.

“I’ve had conversations with Kennedy, we just try to stick to the facts of the evidence,” Hudson said. “There’s not much we can do.

“I just hope that the evidence is enough in the end with all these things,” he added. 



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Iran war: Oil prices jump above $100 for first time in four years

Published

on

Iran war: Oil prices jump above 0 for first time in four years



Major disruption to energy supplies threatens to push up prices for consumers and businesses around the world.



Source link

Continue Reading

Business

Aramco scrips surge 4%, most in three years – The Times of India

Published

on

Aramco scrips surge 4%, most in three years – The Times of India


Saudi Aramco jumped the most since April 2023 on Sunday as the Iran war entered its second week, prompting supply disruptions that may send oil prices higher when global markets reopen. Shares of the state-backed oil giant climbed as much as 4.9% in Riyadh before paring gains to close up 4.1%, on the first day of trading for the stock since Brent crude prices topped $90 a barrel on Friday.Brent may climb further after UAE and Kuwait started reducing oil production amid a near-closure of Strait of Hormuz waterway, adding to interruptions affecting worldwide energy supply and exports. “For Aramco, we believe that the gain in oil prices would offset a decline in exports,” said Junaid Ansari, head of research and strategy at Kamco Investment Co. “We also believe that Aramco should be able to re-route a bulk of its shipments to the Red Sea. It’s just about logistics and handling the excess capacity.” Aramco has been redirecting oil cargoes to Red Sea facilities on Saudi Arabia’s west coast to avoid the Strait of Hormuz.



Source link

Continue Reading

Business

Gulf war risks global economic shock | The Express Tribune

Published

on

Gulf war risks global economic shock | The Express Tribune



ISLAMABAD:

The Middle East once again stands on the verge of a dangerous escalation. What began as a confrontation between Iran and Israel risks evolving into a broader regional conflict involving the Gulf states and major global powers. Such a development would carry profound implications for global energy security and economic stability.

The big war clouds gathering over the Gulf are not merely a regional security concern. They represent a geopolitical confrontation with the potential to reshape global energy markets, international trade and economic stability. If the current escalation expands into a wider Gulf conflict, the shockwaves will be felt far beyond the Middle East.

The rapidly intensifying tensions in the region risk transforming what began as limited strikes and retaliatory attacks between Iran and Israel, backed by the United States and its allies, into a broader regional confrontation. Increasing missile and drone exchanges have heightened fears that the Gulf Cooperation Council (GCC) states may become directly involved. Should this happen, the Middle East could once again become the epicentre of a conflict with global consequences.

The Gulf occupies a uniquely strategic position in the global economy, both for sea and air routes. Nearly one-third of the world’s seaborne oil trade passes through the Strait of Hormuz, making it one of the most sensitive chokepoints in international commerce. Even a temporary disruption in this narrow corridor can trigger volatility in energy markets, driving up oil and LNG prices, increasing transport costs and fuelling inflation worldwide.

History offers a sobering reminder that conflicts in the Gulf rarely remain localised. From the Iran-Iraq war in the 1980s to the Gulf wars that followed, instability in the region has repeatedly reshaped global energy markets and geopolitical alliances. The current escalation carries similar risks at a time when the global economy is already grappling with inflation, supply chain disruptions and geopolitical fragmentation.

Beyond the immediate military dimension, the crisis must also be understood within the broader context of global power competition. The Middle East has long been central to international geopolitics due to its vast energy reserves and its geographic location linking Asia, Europe and Africa. Control over energy supply routes has historically been a key determinant of global influence.

In today’s evolving geopolitical landscape, this factor has gained renewed significance. China, now one of the world’s largest energy consumers, relies heavily on oil imports from the Middle East. Any disruption in regional energy supplies would therefore have consequences not only for global energy markets but also for the balance of economic power among major economies.

Behind the immediate military confrontation lies a deeper strategic contest shaping global geopolitics. The Gulf remains central to the control of energy flows that sustain the world economy, and influence over these supply routes has historically translated into geopolitical leverage. As emerging economies, particularly China, depend heavily on Middle Eastern energy imports, disruptions or shifts in regional alliances could alter the balance of economic influence among major global powers. In this sense, the current escalation reflects not only regional rivalries but also a broader strategic competition unfolding across the international system.

For the Gulf states themselves, the stakes are particularly high. Over the past several decades, many GCC economies have pursued ambitious strategies to diversify beyond oil by investing in financial services, logistics, real estate development, tourism and advanced industries. These economic transformation plans depend heavily on regional stability, peace and investor confidence.

A prolonged military confrontation would threaten these gains. Conflict in the initial days has already disrupted airlines and shipping routes, endangered energy infrastructure and triggered capital flight from regional markets. Brent surged near $85 per barrel. LNG shipping rates soared 650% to $300,000 per day. QatarEnergy declared force majeure, shut down production and halted LNG supplies. Export cargoes of essential food commodities such as rice, fresh fruits and vegetables have halted at various points of origin, endangering the food security of GCC states, particularly those small states with limited local production.

Rising defence expenditures may also divert resources away from long-term development priorities such as infrastructure, education and technological innovation. Another troubling dimension of the current tensions is the risk that geopolitical rivalry may increasingly be framed through sectarian narratives. Relations between Iran and several Gulf states already contain elements of Sunni-Shia competition. If the confrontation intensifies, sectarian polarisation could deepen divisions across the region and make diplomatic solutions more difficult.

Such a development would weaken the Muslim world economically and politically and may send it back to conditions reminiscent of the 1960s. Instead of focusing on economic modernisation, innovation and human capital development, states could find themselves allocating growing resources to defence procurement and military alliances.

For countries like Pakistan, the economic consequences of a wider Gulf war would be immediate and significant. Pakistan remains heavily dependent on imported fuel from Saudi Arabia, the wider Middle East and LNG from Qatar. Food commodities are imported from global sources, and any sharp increase in global energy, shipping costs and food prices would widen the country’s trade deficit by around $4-5 billion and intensify inflationary pressures, while exacerbating the current account deficit.

Furthermore, Pakistan’s external trade relies substantially on foreign shipping companies. War-risk insurance premiums, higher sea freight charges and disruptions in maritime routes would raise the cost of both imports and exports. These pressures would further strain an economy already navigating fiscal and external sector challenges.

Remittances present another important concern, providing a cushion for the current account. Millions of Pakistani workers are employed across Gulf economies and send a major share of remittances from Gulf countries. Any economic slowdown or instability in the region could affect employment opportunities and remittance inflows – one of Pakistan’s most vital sources of foreign exchange and rupee stability.

At this critical moment, restraint and diplomacy are essential. Escalation may serve short-term strategic objectives, but the long-term costs of a wider regional war would be immense. The Middle East has already endured decades of instability and conflict; another large-scale confrontation would deepen humanitarian suffering while undermining economic progress.

History offers a clear lesson: wars in the Gulf rarely remain confined to the region. They reshape global markets, redraw alliances and influence the trajectory of the world economy. Preventing such an outcome requires diplomacy, dialogue and leadership capable of recognising the heavy cost of further escalation.

The Gulf has long been the world’s energy heartland; turning it into a battlefield would endanger not only regional stability but the foundations of the global economy itself.

The writer is a former vice president of KCCI, an independent economic analyst focusing on global trade, energy economics and geopolitical risk



Source link

Continue Reading

Trending